GLIMEPIRIDE- glimepiride tablet

Quốc gia: Hoa Kỳ

Ngôn ngữ: Tiếng Anh

Nguồn: NLM (National Library of Medicine)

Thành phần hoạt chất:

GLIMEPIRIDE (UNII: 6KY687524K) (GLIMEPIRIDE - UNII:6KY687524K)

Sẵn có từ:

NuCare Pharmaceuticals, Inc.

Tuyến hành chính:

ORAL

Loại thuốc theo toa:

PRESCRIPTION DRUG

Chỉ dẫn điều trị:

Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ] . Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets USP are contraindicated in patients with a history of a hypersensitivity reaction to: - Glimepiride or any of the product's ingredients [see Warnings and Precautions (5.2) ] . Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives. Reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g. anaphylaxis, angioedema, Stevens-Johnson Syndrome, dyspnea) [see Warnings and Precautions

Tóm tắt sản phẩm:

Glimepiride tablets USP are available in the following strengths and package sizes: 2 mg (Yellow coloured capsule shaped flat faced, bevelled edged tablets with breakline on both sides and debossed with 'I' and '2' on either side of breakline only on one side) Bottles of 30 NDC 68071-3024-3 Bottles of 60 NDC 68071-3024-6 Bottles of 90 NDC 68071-3024-9 Bottles of 180 NDC 68071-3024-8 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] Dispense in well-closed containers with safety closures.

Tình trạng ủy quyền:

Abbreviated New Drug Application

Đặc tính sản phẩm

GLIMEPIRIDE- GLIMEPIRIDE TABLET
NUCARE PHARMACEUTICALS, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
GLIMEPIRIDE TABLETS USP SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GLIMEPIRIDE TABLETS
USP.
GLIMEPIRIDE TABLETS USP
INITIAL U.S. APPROVAL: 1995
INDICATIONS AND USAGE
Glimepiride tablets USP is a sulfonylurea indicated as an adjunct to
diet and exercise to improve glycemic control in adults
with type 2 diabetes mellitus ( 1.1).
Important Limitations of Use:
Not for treating type 1 diabetes mellitus or diabetic ketoacidosis (
1.1).
DOSAGE AND ADMINISTRATION
Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2
mg increments no more frequently than every
1-2 weeks based on glycemic response. Maximum recommended dose is 8 mg
once daily ( 2.1).
Administer with breakfast or first meal of the day ( 2.1).
Use 1 mg starting dose and titrate slowly in patients at increased
risk for hypoglycemia (e.g., elderly, patients with renal
impairment) ( 2.1).
DOSAGE FORMS AND STRENGTHS
Tablets (scored): 1 mg, 2 mg, 4 mg ( 3)
CONTRAINDICATIONS
Hypersensitivity to glimepiride or any of the product's ingredients (
4)
Hypersensitivity to sulfonamide derivatives ( 4)
WARNINGS AND PRECAUTIONS
Hypoglycemia: May be severe. Ensure proper patient selection, dosing,
and instructions, particularly in at-risk
populations (e.g., elderly, renally impaired) and when used with other
anti-diabetic medications ( 5.1).
Hypersensitivity Reactions: Postmarketing reports include anaphylaxis,
angioedema and Stevens-Johnson Syndrome.
Promptly discontinue Glimepiride tablets USP, assess for other causes,
institute appropriate monitoring and treatment,
and initiate alternative treatment for diabetes ( 5.2).
Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase
(G6PD) deficient. Consider a non-sulfonylurea
alternative. ( 5.3).
Potential Increased Risk of Cardiovascular Mortality with
Sulfonylureas: Inform patient of risks, benefits and treatme